Real-World Ravulizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population

被引：0
|
作者：
Cheng, Wendy Y. [1 ]
Fishman, Jesse [2 ]
Sarda, Sujata P. [2 ]
Krishnan, Sangeeta [2 ]
Kunzweiler, Colin [1 ]
Vu, Jensen Duy [1 ]
Yenikomshian, Mihran [1 ]
Duh, Mei Sheng [1 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Apellis Pharmaceut Inc, Waltham, MA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4999
引用
收藏
页数：4
相关论文
共 50 条
  • [31] A First Report from the COMPLETE Study on the Real-World Effectiveness of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    de Latour, Regis Peffault
    Trikha, Roochi
    Gonzalez, Carmen Gonzalez
    Nolte, Matthias
    Malmstrom, Hakan
    Lethagen, Stefan
    BLOOD, 2024, 144 : 5669 - 5670
  • [32] Real-World Use of Therapeutic Anticoagulation in Patients with Paroxysmal Nocturnal Hemoglobinuria. Results of a Survey of Physicians in Australia
    Szer, Jeffrey
    Forsyth, Cecily J.
    Giese, Anja
    BLOOD, 2015, 126 (23)
  • [33] Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria
    Fuereder, Wolfgang
    Valent, Peter
    ANNALS OF HEMATOLOGY, 2024, 103 (08) : 3235 - 3238
  • [34] IDENTIFICATION AND DESCRIPTION OF REAL-WORLD DATA SOURCES FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): A REVIEW OF LITERATURE
    Lavudiya, S.
    Agrawal, R.
    Rovira, G.
    Studer, R.
    VALUE IN HEALTH, 2020, 23 : S715 - S715
  • [35] Improvements in Hemoglobin and Cognitive Function from Opera: A Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria
    Fishman, Jesse
    Min, Jinny
    Arnett, Lily
    Shenoy, Apeksha
    BLOOD, 2023, 142
  • [36] Early Insights into Real-World Iptacopan Use Among Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States: The Apprise-PNH Data Platform
    Dingli, David
    Yen, Glorian
    Kuypers, Nicholas
    Paulose, Jincy
    Chanpura, Mohin
    Lee, Soyon
    Barone, Joseph
    Stutts, Jacob
    Buchan, Tayler
    Buchan, Claire
    Kim, Inkyu
    Tang, Jackson
    Waheed, Anem
    BLOOD, 2024, 144 : 5668 - 5669
  • [37] Terminal Complement Inhibition Exhibiting Higher Response in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Multicentric Real-World Evidence in Brazil
    Justino, Caio Cesar
    Yamakawa, Patricia Eiko
    Azambuja, Ana Paula
    Marchesini, Rafael
    Fonseca, Ana Rita
    Gomes, Iara Baldim Rabelo
    Arruda, Martha Mariana Almeida Santos
    Cruz, Lafayette Cavalcanti Bezerra Dias
    Ribeiro, Ferdinando Cesar Batista
    Vasconcelos, Yuri
    Molla, Vinicius Campos de
    Figueiredo, Maria Stella
    Arrais-Rodrigues, Celso
    BLOOD, 2024, 144 : 5689 - 5690
  • [38] Real-World Drug Adherence, Persistence, and Healthcare Resource Utilization in Patients with Paroxysmal Nocturnal Hemoglobinuria in the USA: The Advantage Study
    Griffiths, Elizabeth A.
    Messali, Andrew
    Mahdi, Mohammed
    Dersarkissian, Maral
    Chang, Rose
    Rabideau, Brendan
    Dingli, David
    BLOOD, 2024, 144 : 5074 - 5075
  • [39] Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
    Thomas O’Connell
    Marric Buessing
    Scott Johnson
    Lufei Tu
    Simu K. Thomas
    Ioannis Tomazos
    PharmacoEconomics, 2020, 38 : 981 - 994
  • [40] A Systematic Literature Review of Clinical and Economic Outcomes for Patients with Paroxysmal Nocturnal Hemoglobinuria in Clinical Trials and Real-World Settings
    Waheed, Anem
    Kaufhold, Samantha
    Liu, Che-Rung
    Lei, Jiali
    Nellesen, Dave
    Geevarghese, Anumaxine Lincy
    Yen, Glorian P.
    BLOOD, 2022, 140 : 11451 - 11452
12345